PureTech Health plc (FRA:0VQ)

Germany flag Germany · Delayed Price · Currency is EUR
1.460
+0.040 (2.82%)
Jan 8, 2026, 4:00 PM EST
-16.57%
Market Cap359.87M
Revenue (ttm)5.44M
Net Income (ttm)43.15M
Shares Outn/a
EPS (ttm)0.17
PE Ratio8.34
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume779
Open1.460
Previous Close1.420
Day's Range1.460 - 1.460
52-Week Range1.160 - 1.870
Betan/a
RSI60.39
Earnings DateApr 29, 2026

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 56
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0VQ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.